Research Paper Reviews
Thymosin β4 reviews and the fragment sold as TB-500 are not the same citation
Goldstein’s 2012 review covers full-length thymosin β4. Malinda’s 1999 wound study is a mouse paper. Neither is a trial of every vial labeled TB-500.
Thymosin β4 is a 43-amino-acid actin-binding peptide. Goldstein, Hannappel, Sosne, and Kleinman reviewed it in 2012 as a regenerative molecule with wound, corneal, and cardiac lines of research, including early clinical applications of the full-length peptide. That review is about thymosin β4. Catalogs often sell “TB-500” and parenthetically equate it with thymosin β4. Readers should look at the sequence the seller claims. A fragment is not automatically the molecule in the review.
The wound-healing mouse paper
Malinda and colleagues, Journal of Investigative Dermatology, 1999, reported faster re-epithelialization in a murine wound model. It is a real preclinical result and a frequently inherited citation. It used experimental wounds in mice. It did not measure return-to-sport, and it did not test a blended vial that also contains BPC-157 and GHK-Cu.
How to cite this without inflating it
Write “a 1999 mouse wound study reported faster re-epithelialization with thymosin β4” and link PMID 10469335. Write “a 2012 review summarized regenerative lines of research” and link PMID 22074294. Do not write “TB-500 is clinically proven” on the back of either sentence. If a later human trial of a specific thymosin β4 formulation exists, it deserves its own link. This summary does not borrow one.